Interleukin-37 is increased in adult-onset Still’s disease and associated with disease activity

Interleukin (IL)-37 has been known to play an immunosuppressive role in various inflammatory disorders, but whether it participates in the regulation of pathogenesis of adult-onset Still's disease (AOSD) has not been investigated. In this study, we examined serum IL-37 levels and their clinical...

Full description

Saved in:
Bibliographic Details
Published inArthritis research & therapy Vol. 20; no. 1; pp. 54 - 12
Main Authors Chi, Huihui, Liu, Dongzhou, Sun, Yue, Hu, Qiongyi, Liu, Honglei, Cheng, Xiaobing, Ye, Junna, Shi, Hui, Yin, Yufeng, Liu, Mengru, Wu, Xinyao, Zhou, Zhuochao, Teng, Jialin, Yang, Chengde, Su, Yutong
Format Journal Article
LanguageEnglish
Published England BioMed Central Ltd 22.03.2018
BioMed Central
BMC
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Interleukin (IL)-37 has been known to play an immunosuppressive role in various inflammatory disorders, but whether it participates in the regulation of pathogenesis of adult-onset Still's disease (AOSD) has not been investigated. In this study, we examined serum IL-37 levels and their clinical association with AOSD, and we explored the anti-inflammatory effects of IL-37 on peripheral blood mononuclear cells (PBMCs) from patients with AOSD. Blood samples were collected from 62 patients with AOSD and 50 healthy control subjects (HC). The serum IL-37 levels were determined using an enzyme-linked immunosorbent assay (ELISA). The correlations of serum IL-37 levels with disease activity, laboratory values, and inflammatory cytokines in AOSD were analyzed by Spearman's correlation test. The correlations between serum IL-37 levels and clinical manifestations were analyzed by Mann-Whitney U test. PBMCs from ten patients with AOSD were stimulated with recombinant human IL-37 protein, and expression levels of tumor necrosis factor (TNF)-α, IL-6, IL-10, IL-1β, and IL-18 were determined by qRT-PCR and ELISA. A significantly higher IL-37 protein level was observed in patients with AOSD than in HC. Serum IL-37 levels correlated with systemic score, laboratory values, IL-1β, IL-18, and IL-10 in patients with AOSD. The expression levels of IL-37 were closely related to the patients with AOSD who also had fever, skin rash, lymphadenopathy, splenomegaly, myalgia, and arthralgia. Moreover, the production of proinflammatory cytokines such as IL-6, IL-1β, TNF-α, and IL-18 in PBMCs from patients with AOSD was obviously attenuated after recombinant human IL-37 stimulation. Increased expression of IL-37 and its positive correlation with disease activity suggest its involvement in AOSD pathogenesis. More importantly, IL-37 inhibits the expression of proinflammatory cytokines in PBMCs from patients with AOSD, indicating the potential anti-inflammatory role of IL-37 in AOSD. Thus, IL-37 may be a novel disease activity biomarker and research target in AOSD.
AbstractList Abstract Background Interleukin (IL)-37 has been known to play an immunosuppressive role in various inflammatory disorders, but whether it participates in the regulation of pathogenesis of adult-onset Still’s disease (AOSD) has not been investigated. In this study, we examined serum IL-37 levels and their clinical association with AOSD, and we explored the anti-inflammatory effects of IL-37 on peripheral blood mononuclear cells (PBMCs) from patients with AOSD. Methods Blood samples were collected from 62 patients with AOSD and 50 healthy control subjects (HC). The serum IL-37 levels were determined using an enzyme-linked immunosorbent assay (ELISA). The correlations of serum IL-37 levels with disease activity, laboratory values, and inflammatory cytokines in AOSD were analyzed by Spearman’s correlation test. The correlations between serum IL-37 levels and clinical manifestations were analyzed by Mann-Whitney U test. PBMCs from ten patients with AOSD were stimulated with recombinant human IL-37 protein, and expression levels of tumor necrosis factor (TNF)-α, IL-6, IL-10, IL-1β, and IL-18 were determined by qRT-PCR and ELISA. Results A significantly higher IL-37 protein level was observed in patients with AOSD than in HC. Serum IL-37 levels correlated with systemic score, laboratory values, IL-1β, IL-18, and IL-10 in patients with AOSD. The expression levels of IL-37 were closely related to the patients with AOSD who also had fever, skin rash, lymphadenopathy, splenomegaly, myalgia, and arthralgia. Moreover, the production of proinflammatory cytokines such as IL-6, IL-1β, TNF-α, and IL-18 in PBMCs from patients with AOSD was obviously attenuated after recombinant human IL-37 stimulation. Conclusions Increased expression of IL-37 and its positive correlation with disease activity suggest its involvement in AOSD pathogenesis. More importantly, IL-37 inhibits the expression of proinflammatory cytokines in PBMCs from patients with AOSD, indicating the potential anti-inflammatory role of IL-37 in AOSD. Thus, IL-37 may be a novel disease activity biomarker and research target in AOSD.
Interleukin (IL)-37 has been known to play an immunosuppressive role in various inflammatory disorders, but whether it participates in the regulation of pathogenesis of adult-onset Still's disease (AOSD) has not been investigated. In this study, we examined serum IL-37 levels and their clinical association with AOSD, and we explored the anti-inflammatory effects of IL-37 on peripheral blood mononuclear cells (PBMCs) from patients with AOSD.BACKGROUNDInterleukin (IL)-37 has been known to play an immunosuppressive role in various inflammatory disorders, but whether it participates in the regulation of pathogenesis of adult-onset Still's disease (AOSD) has not been investigated. In this study, we examined serum IL-37 levels and their clinical association with AOSD, and we explored the anti-inflammatory effects of IL-37 on peripheral blood mononuclear cells (PBMCs) from patients with AOSD.Blood samples were collected from 62 patients with AOSD and 50 healthy control subjects (HC). The serum IL-37 levels were determined using an enzyme-linked immunosorbent assay (ELISA). The correlations of serum IL-37 levels with disease activity, laboratory values, and inflammatory cytokines in AOSD were analyzed by Spearman's correlation test. The correlations between serum IL-37 levels and clinical manifestations were analyzed by Mann-Whitney U test. PBMCs from ten patients with AOSD were stimulated with recombinant human IL-37 protein, and expression levels of tumor necrosis factor (TNF)-α, IL-6, IL-10, IL-1β, and IL-18 were determined by qRT-PCR and ELISA.METHODSBlood samples were collected from 62 patients with AOSD and 50 healthy control subjects (HC). The serum IL-37 levels were determined using an enzyme-linked immunosorbent assay (ELISA). The correlations of serum IL-37 levels with disease activity, laboratory values, and inflammatory cytokines in AOSD were analyzed by Spearman's correlation test. The correlations between serum IL-37 levels and clinical manifestations were analyzed by Mann-Whitney U test. PBMCs from ten patients with AOSD were stimulated with recombinant human IL-37 protein, and expression levels of tumor necrosis factor (TNF)-α, IL-6, IL-10, IL-1β, and IL-18 were determined by qRT-PCR and ELISA.A significantly higher IL-37 protein level was observed in patients with AOSD than in HC. Serum IL-37 levels correlated with systemic score, laboratory values, IL-1β, IL-18, and IL-10 in patients with AOSD. The expression levels of IL-37 were closely related to the patients with AOSD who also had fever, skin rash, lymphadenopathy, splenomegaly, myalgia, and arthralgia. Moreover, the production of proinflammatory cytokines such as IL-6, IL-1β, TNF-α, and IL-18 in PBMCs from patients with AOSD was obviously attenuated after recombinant human IL-37 stimulation.RESULTSA significantly higher IL-37 protein level was observed in patients with AOSD than in HC. Serum IL-37 levels correlated with systemic score, laboratory values, IL-1β, IL-18, and IL-10 in patients with AOSD. The expression levels of IL-37 were closely related to the patients with AOSD who also had fever, skin rash, lymphadenopathy, splenomegaly, myalgia, and arthralgia. Moreover, the production of proinflammatory cytokines such as IL-6, IL-1β, TNF-α, and IL-18 in PBMCs from patients with AOSD was obviously attenuated after recombinant human IL-37 stimulation.Increased expression of IL-37 and its positive correlation with disease activity suggest its involvement in AOSD pathogenesis. More importantly, IL-37 inhibits the expression of proinflammatory cytokines in PBMCs from patients with AOSD, indicating the potential anti-inflammatory role of IL-37 in AOSD. Thus, IL-37 may be a novel disease activity biomarker and research target in AOSD.CONCLUSIONSIncreased expression of IL-37 and its positive correlation with disease activity suggest its involvement in AOSD pathogenesis. More importantly, IL-37 inhibits the expression of proinflammatory cytokines in PBMCs from patients with AOSD, indicating the potential anti-inflammatory role of IL-37 in AOSD. Thus, IL-37 may be a novel disease activity biomarker and research target in AOSD.
Interleukin (IL)-37 has been known to play an immunosuppressive role in various inflammatory disorders, but whether it participates in the regulation of pathogenesis of adult-onset Still's disease (AOSD) has not been investigated. In this study, we examined serum IL-37 levels and their clinical association with AOSD, and we explored the anti-inflammatory effects of IL-37 on peripheral blood mononuclear cells (PBMCs) from patients with AOSD. Blood samples were collected from 62 patients with AOSD and 50 healthy control subjects (HC). The serum IL-37 levels were determined using an enzyme-linked immunosorbent assay (ELISA). The correlations of serum IL-37 levels with disease activity, laboratory values, and inflammatory cytokines in AOSD were analyzed by Spearman's correlation test. The correlations between serum IL-37 levels and clinical manifestations were analyzed by Mann-Whitney U test. PBMCs from ten patients with AOSD were stimulated with recombinant human IL-37 protein, and expression levels of tumor necrosis factor (TNF)-α, IL-6, IL-10, IL-1β, and IL-18 were determined by qRT-PCR and ELISA. A significantly higher IL-37 protein level was observed in patients with AOSD than in HC. Serum IL-37 levels correlated with systemic score, laboratory values, IL-1β, IL-18, and IL-10 in patients with AOSD. The expression levels of IL-37 were closely related to the patients with AOSD who also had fever, skin rash, lymphadenopathy, splenomegaly, myalgia, and arthralgia. Moreover, the production of proinflammatory cytokines such as IL-6, IL-1β, TNF-α, and IL-18 in PBMCs from patients with AOSD was obviously attenuated after recombinant human IL-37 stimulation. Increased expression of IL-37 and its positive correlation with disease activity suggest its involvement in AOSD pathogenesis. More importantly, IL-37 inhibits the expression of proinflammatory cytokines in PBMCs from patients with AOSD, indicating the potential anti-inflammatory role of IL-37 in AOSD. Thus, IL-37 may be a novel disease activity biomarker and research target in AOSD.
ArticleNumber 54
Audience Academic
Author Wu, Xinyao
Sun, Yue
Yin, Yufeng
Chi, Huihui
Shi, Hui
Liu, Honglei
Cheng, Xiaobing
Ye, Junna
Liu, Mengru
Su, Yutong
Zhou, Zhuochao
Liu, Dongzhou
Yang, Chengde
Hu, Qiongyi
Teng, Jialin
Author_xml – sequence: 1
  givenname: Huihui
  surname: Chi
  fullname: Chi, Huihui
– sequence: 2
  givenname: Dongzhou
  surname: Liu
  fullname: Liu, Dongzhou
– sequence: 3
  givenname: Yue
  surname: Sun
  fullname: Sun, Yue
– sequence: 4
  givenname: Qiongyi
  surname: Hu
  fullname: Hu, Qiongyi
– sequence: 5
  givenname: Honglei
  surname: Liu
  fullname: Liu, Honglei
– sequence: 6
  givenname: Xiaobing
  surname: Cheng
  fullname: Cheng, Xiaobing
– sequence: 7
  givenname: Junna
  surname: Ye
  fullname: Ye, Junna
– sequence: 8
  givenname: Hui
  surname: Shi
  fullname: Shi, Hui
– sequence: 9
  givenname: Yufeng
  surname: Yin
  fullname: Yin, Yufeng
– sequence: 10
  givenname: Mengru
  surname: Liu
  fullname: Liu, Mengru
– sequence: 11
  givenname: Xinyao
  surname: Wu
  fullname: Wu, Xinyao
– sequence: 12
  givenname: Zhuochao
  surname: Zhou
  fullname: Zhou, Zhuochao
– sequence: 13
  givenname: Jialin
  surname: Teng
  fullname: Teng, Jialin
– sequence: 14
  givenname: Chengde
  surname: Yang
  fullname: Yang, Chengde
– sequence: 15
  givenname: Yutong
  surname: Su
  fullname: Su, Yutong
BackLink https://www.ncbi.nlm.nih.gov/pubmed/29566725$$D View this record in MEDLINE/PubMed
BookMark eNp9kstu1TAQhiNURC_wAGxQJDZsUnyJL2eDVFUUjlSJBbC2Js7k1MXHLrFT1B2v0dfjSXBIKT0IIUv2aOb7f43tOaz2QgxYVc8pOaZUy9eJcqJEQ6huqBCikY-qA9oq3Ugu2d6DeL86TOmSEMZWrH1S7bOVkFIxcVDBOmQcPU5fXGi4ql2qXbAjQsK-RDX0k89NDAlz_TE77398v01179JM1BD6GlKK1kEu_DeXL_7UbHbXLt88rR4P4BM-uzuPqs9nbz-dvm_OP7xbn56cN1ZwlhsKCnqNEi0I1kkr5w04qqEdpLUSNbaCMo1ECM16q4ATpjkbtNKak5YfVevFt49waa5Gt4XxxkRw5lcijhsDY3bWo5FdNwxKrBjRom35oJFxWPFWqV6KDnnxerN4XU3dFnuLIY_gd0x3K8FdmE28NkJLrlaqGLy6Mxjj1wlTNluXLHoPAeOUDCt_RijXVBT05YJuoLTmwhCLo51xcyJayVpO5Gx4_A-qrB63zpaxGFzJ7whePLzCfe-_v74AdAHsGFMacbhHKDHzeJllvExp1czjZWTRqL801mXILs6v4Px_lD8BMjnT_Q
CitedBy_id crossref_primary_10_1093_rheumatology_keab485
crossref_primary_10_1080_02770903_2021_1878533
crossref_primary_10_1080_14737159_2019_1615449
crossref_primary_10_3389_fimmu_2021_708425
crossref_primary_10_3389_fimmu_2021_654811
crossref_primary_10_3389_fimmu_2020_603389
crossref_primary_10_1007_s00393_022_01276_4
crossref_primary_10_1016_j_semarthrit_2021_06_004
crossref_primary_10_1093_rheumatology_kead507
crossref_primary_10_1007_s10067_018_4288_7
crossref_primary_10_1016_S2665_9913_24_00225_X
crossref_primary_10_1038_s41584_019_0277_8
crossref_primary_10_1007_s00393_022_01294_2
crossref_primary_10_47360_1995_4484_2021_643_663
crossref_primary_10_1080_08820139_2024_2443253
crossref_primary_10_3390_jcm11082232
crossref_primary_10_47360_1995_4484_2022_195_204
crossref_primary_10_1097_MD_0000000000023579
crossref_primary_10_1186_s12967_018_1655_8
crossref_primary_10_1007_s10067_020_05094_4
crossref_primary_10_3389_fmed_2020_566738
crossref_primary_10_1186_s43166_021_00065_2
crossref_primary_10_1080_17520363_2024_2403330
crossref_primary_10_3389_fmed_2022_881431
crossref_primary_10_3390_ijms232112810
crossref_primary_10_1097_CM9_0000000000000538
crossref_primary_10_3389_fmed_2019_00266
crossref_primary_10_3389_fimmu_2020_02112
crossref_primary_10_1007_s10067_019_04642_x
crossref_primary_10_1016_j_cytogfr_2019_10_003
crossref_primary_10_1155_2021_6650928
crossref_primary_10_3390_jcm10050910
crossref_primary_10_3390_ijms24010372
crossref_primary_10_1080_1744666X_2018_1533403
Cites_doi 10.1371/journal.ppat.1004462
10.1016/j.autrev.2014.08.032
10.3109/03009742.2014.992949
10.1186/s12967-015-0394-3
10.1093/rheumatology/keq133
10.1155/2012/317820
10.1093/rheumatology/kew325
10.1093/rheumatology/kew300
10.1007/s10067-013-2381-5
10.1093/rheumatology/keq284
10.1155/2012/156890
10.1016/j.berh.2008.08.006
10.3389/fphar.2017.00369
10.1093/rheumatology/ket250
10.1073/pnas.1619667114
10.1684/ecn.2011.0288
10.1016/j.cyto.2015.06.005
10.1089/bio.2015.0104
10.1093/rheumatology/40.12.1398
10.1016/j.semarthrit.2012.03.004
10.1111/cei.12061
10.1210/en.2016-1167
10.1155/2012/964751
10.4049/jimmunol.1401810
10.1111/imr.12605
10.1038/ni.1944
10.1038/nrrheum.2011.68
10.1002/art.1780300209
10.1038/sj.gene.6363922
10.1002/acr.22194
10.1097/00005792-199103000-00004
10.1016/j.cyto.2014.11.025
10.1186/1479-5876-12-69
10.1016/j.berh.2016.08.003
10.1073/pnas.1416714111
10.1155/2012/879020
10.1002/1529-0131(200107)44:7<1716::AID-ART298>3.0.CO;2-I
10.1136/ard.2003.013680
10.1016/j.autrev.2017.07.017
10.1111/1346-8138.13888
10.1136/ard.47.9.764
10.1073/pnas.1619011114
10.1097/MD.0000000000001554
10.1073/pnas.1523212113
10.1002/art.22981
10.1371/journal.pone.0107183
10.1016/j.cyto.2012.11.025
10.1016/0140-6736(93)91184-N
10.3899/jrheum.100247
10.3109/s10165-008-0065-9
10.3109/07853890.2014.971052
10.1016/j.autrev.2014.01.058
10.1002/1529-0131(200103)44:3<550::AID-ANR103>3.0.CO;2-5
10.1586/17476348.2015.1109452
10.1371/journal.pone.0095346
ContentType Journal Article
Copyright COPYRIGHT 2018 BioMed Central Ltd.
The Author(s). 2018
Copyright_xml – notice: COPYRIGHT 2018 BioMed Central Ltd.
– notice: The Author(s). 2018
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
DOA
DOI 10.1186/s13075-018-1555-6
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList
MEDLINE - Academic
MEDLINE
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1478-6362
EndPage 12
ExternalDocumentID oai_doaj_org_article_6bbff7592085443f8e23a93477d65be3
PMC5863797
A546243067
29566725
10_1186_s13075_018_1555_6
Genre Research Support, Non-U.S. Gov't
Journal Article
GrantInformation_xml – fundername: ;
  grantid: 81671589; 81601400
– fundername: ;
  grantid: GCQN-2017-B04
– fundername: ;
  grantid: YG2016QN62
– fundername: ;
  grantid: 17411965100
– fundername: ;
  grantid: 16YF1407000
GroupedDBID ---
.GJ
0R~
23N
2WC
4.4
5GY
5VS
6J9
7X7
88E
8FI
8FJ
AAFWJ
AAJSJ
AASML
AAYXX
ABUWG
ACGFS
ACJQM
ADBBV
ADUKV
AEGXH
AENEX
AFKRA
AFPKN
AHBYD
AHMBA
AHYZX
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AOIAM
AOIJS
BAPOH
BAWUL
BCNDV
BENPR
BFQNJ
BMC
BPHCQ
BVXVI
C6C
CCPQU
CITATION
CS3
DIK
E3Z
EBD
EBLON
EJD
EMOBN
F5P
FYUFA
GROUPED_DOAJ
GX1
H13
HMCUK
HYE
HZ~
INH
INR
ITC
KQ8
M1P
O5R
O5S
O9-
PGMZT
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
PSQYO
RBZ
ROL
RPM
RSV
SMD
SOJ
SV3
TR2
U2A
UKHRP
WOQ
-5E
-5G
-A0
-BR
3V.
ACRMQ
ADINQ
C24
CGR
CUY
CVF
ECM
EIF
IAO
IHR
NPM
Z7U
PMFND
7X8
PJZUB
PPXIY
5PM
PUEGO
ID FETCH-LOGICAL-c532t-1a7ad8e6eca52b6c62b6ca3e7f4f6cc6e8e45128e05582dc7a302832f87883043
IEDL.DBID DOA
ISSN 1478-6362
1478-6354
IngestDate Wed Aug 27 01:31:53 EDT 2025
Thu Aug 21 13:28:57 EDT 2025
Mon Jul 21 11:42:07 EDT 2025
Tue Jun 17 21:36:48 EDT 2025
Tue Jun 10 20:22:37 EDT 2025
Wed Feb 19 02:35:56 EST 2025
Thu Apr 24 23:08:36 EDT 2025
Tue Jul 01 04:00:50 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords Peripheral blood mononuclear cells
IL-37
Adult-onset Still’s disease
Cytokines
Language English
License Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c532t-1a7ad8e6eca52b6c62b6ca3e7f4f6cc6e8e45128e05582dc7a302832f87883043
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink https://doaj.org/article/6bbff7592085443f8e23a93477d65be3
PMID 29566725
PQID 2018013815
PQPubID 23479
PageCount 12
ParticipantIDs doaj_primary_oai_doaj_org_article_6bbff7592085443f8e23a93477d65be3
pubmedcentral_primary_oai_pubmedcentral_nih_gov_5863797
proquest_miscellaneous_2018013815
gale_infotracmisc_A546243067
gale_infotracacademiconefile_A546243067
pubmed_primary_29566725
crossref_primary_10_1186_s13075_018_1555_6
crossref_citationtrail_10_1186_s13075_018_1555_6
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2018-03-22
PublicationDateYYYYMMDD 2018-03-22
PublicationDate_xml – month: 03
  year: 2018
  text: 2018-03-22
  day: 22
PublicationDecade 2010
PublicationPlace England
PublicationPlace_xml – name: England
– name: London
PublicationTitle Arthritis research & therapy
PublicationTitleAlternate Arthritis Res Ther
PublicationYear 2018
Publisher BioMed Central Ltd
BioMed Central
BMC
Publisher_xml – name: BioMed Central Ltd
– name: BioMed Central
– name: BMC
References AT Maria (1555_CR8) 2014; 13
C Girard (1555_CR40) 2016; 55
CP Mavragani (1555_CR45) 2012; 2012
G Cavalli (1555_CR29) 2018; 281
T Sugiura (1555_CR9) 2002; 3
H Imaeda (1555_CR51) 2013; 172
M Gerfaud-Valentin (1555_CR3) 2014; 13
T Ito (1555_CR53) 2008; 18
F Ortiz-Sanjuán (1555_CR17) 2015; 94
T Fujii (1555_CR19) 2001; 40
S Colafrancesco (1555_CR13) 2012; 2012
IA Al-Homood (1555_CR43) 2014; 53
J Pouchot (1555_CR7) 1993; 341
B Chen (1555_CR28) 2015; 13
DY Chen (1555_CR49) 2004; 63
L Lunding (1555_CR56) 2015; 9
Y Luo (1555_CR57) 2014; 111
S Moretti (1555_CR58) 2014; 10
S Castañeda (1555_CR1) 2016; 30
M Shimizu (1555_CR47) 2010; 49
G Cavalli (1555_CR22) 2015; 44
T Takeichi (1555_CR60) 2017; 44
A Kontzias (1555_CR16) 2012; 42
C Giampietro (1555_CR14) 2012; 2012
M Kawashima (1555_CR10) 2001; 44
T Hoshino (1555_CR12) 1998; 25
MF Nold (1555_CR31) 2010; 11
M Shimizu (1555_CR48) 2013; 61
JM Wouters (1555_CR6) 1988; 47
J Pouchot (1555_CR38) 1991; 70
HW Grievink (1555_CR41) 2016; 14
L Xia (1555_CR25) 2015; 76
P Efthimiou (1555_CR5) 2012; 2012
PW Zhao (1555_CR30) 2014; 9
G Cavalli (1555_CR27) 2016; 55
JJ Cush (1555_CR46) 1987; 30
Y Li (1555_CR36) 2014; 9
M Rau (1555_CR39) 2010; 37
JH Choi (1555_CR50) 2003; 30
P Cipriani (1555_CR15) 2014; 33
S Colafrancesco (1555_CR23) 2017; 8
L Ye (1555_CR26) 2015; 194
Y Su (1555_CR42) 2016; 157
HM Chen (1555_CR59) 2015; 72
Q Zeng (1555_CR35) 2017; 114
M Coll-Miró (1555_CR33) 2016; 113
DY Chen (1555_CR44) 2010; 49
H Ichida (1555_CR20) 2014; 66
Y Kawaguchi (1555_CR11) 2001; 44
ED Mellins (1555_CR54) 2011; 7
L Ye (1555_CR24) 2014; 12
1555_CR2
G Cavalli (1555_CR34) 2017; 114
J Huang (1555_CR55) 2016; 15
D Boraschi (1555_CR32) 2011; 22
B Fautrel (1555_CR4) 2008; 22
N Fall (1555_CR52) 2007; 56
M Govoni (1555_CR21) 2017; 16
M Yamaguchi (1555_CR37) 1992; 19
DY Chen (1555_CR18) 2004; 31
References_xml – volume: 10
  start-page: e1004462
  issue: 11
  year: 2014
  ident: 1555_CR58
  publication-title: PLoS Pathog
  doi: 10.1371/journal.ppat.1004462
– volume: 13
  start-page: 1149
  issue: 11
  year: 2014
  ident: 1555_CR8
  publication-title: Autoimmun Rev
  doi: 10.1016/j.autrev.2014.08.032
– volume: 44
  start-page: 309
  issue: 4
  year: 2015
  ident: 1555_CR22
  publication-title: Scand J Rheumatol
  doi: 10.3109/03009742.2014.992949
– volume: 13
  start-page: 36
  year: 2015
  ident: 1555_CR28
  publication-title: J Transl Med
  doi: 10.1186/s12967-015-0394-3
– volume: 49
  start-page: 1645
  issue: 9
  year: 2010
  ident: 1555_CR47
  publication-title: Rheumatology (Oxford)
  doi: 10.1093/rheumatology/keq133
– volume: 31
  start-page: 2189
  issue: 11
  year: 2004
  ident: 1555_CR18
  publication-title: J Rheumatol
– volume: 25
  start-page: 396
  issue: 2
  year: 1998
  ident: 1555_CR12
  publication-title: J Rheumatol
– volume: 2012
  start-page: 317820
  year: 2012
  ident: 1555_CR14
  publication-title: Int J Inflamm
  doi: 10.1155/2012/317820
– volume: 55
  start-page: 2220
  issue: 12
  year: 2016
  ident: 1555_CR27
  publication-title: Rheumatology (Oxford)
  doi: 10.1093/rheumatology/kew325
– volume: 55
  start-page: 2237
  issue: 12
  year: 2016
  ident: 1555_CR40
  publication-title: Rheumatology (Oxford)
  doi: 10.1093/rheumatology/kew300
– volume: 33
  start-page: 49
  issue: 1
  year: 2014
  ident: 1555_CR15
  publication-title: Clin Rheumatol
  doi: 10.1007/s10067-013-2381-5
– volume: 49
  start-page: 2305
  issue: 12
  year: 2010
  ident: 1555_CR44
  publication-title: Rheumatology (Oxford)
  doi: 10.1093/rheumatology/keq284
– volume: 2012
  start-page: 156890
  year: 2012
  ident: 1555_CR13
  publication-title: Int J Inflamm
  doi: 10.1155/2012/156890
– volume: 22
  start-page: 773
  issue: 5
  year: 2008
  ident: 1555_CR4
  publication-title: Best Pract Res Clin Rheumatol
  doi: 10.1016/j.berh.2008.08.006
– volume: 8
  start-page: 369
  year: 2017
  ident: 1555_CR23
  publication-title: Front Pharmacol
  doi: 10.3389/fphar.2017.00369
– volume: 53
  start-page: 32
  issue: 1
  year: 2014
  ident: 1555_CR43
  publication-title: Rheumatology (Oxford)
  doi: 10.1093/rheumatology/ket250
– volume: 114
  start-page: 1631
  issue: 7
  year: 2017
  ident: 1555_CR35
  publication-title: Proc Natl Acad Sci U S A
  doi: 10.1073/pnas.1619667114
– volume: 22
  start-page: 127
  issue: 3
  year: 2011
  ident: 1555_CR32
  publication-title: Eur Cytokine Netw
  doi: 10.1684/ecn.2011.0288
– volume: 76
  start-page: 553
  issue: 2
  year: 2015
  ident: 1555_CR25
  publication-title: Cytokine
  doi: 10.1016/j.cyto.2015.06.005
– volume: 14
  start-page: 410
  issue: 5
  year: 2016
  ident: 1555_CR41
  publication-title: Biopreserv Biobank
  doi: 10.1089/bio.2015.0104
– volume: 40
  start-page: 1398
  issue: 12
  year: 2001
  ident: 1555_CR19
  publication-title: Rheumatology (Oxford)
  doi: 10.1093/rheumatology/40.12.1398
– volume: 42
  start-page: 201
  issue: 2
  year: 2012
  ident: 1555_CR16
  publication-title: Semin Arthritis Rheum
  doi: 10.1016/j.semarthrit.2012.03.004
– volume: 19
  start-page: 424
  issue: 3
  year: 1992
  ident: 1555_CR37
  publication-title: J Rheumatol
– volume: 172
  start-page: 410
  issue: 3
  year: 2013
  ident: 1555_CR51
  publication-title: Clin Exp Immunol
  doi: 10.1111/cei.12061
– volume: 157
  start-page: 4782
  issue: 12
  year: 2016
  ident: 1555_CR42
  publication-title: Endocrinology
  doi: 10.1210/en.2016-1167
– volume: 2012
  start-page: 964751
  year: 2012
  ident: 1555_CR5
  publication-title: Int J Inflamm
  doi: 10.1155/2012/964751
– volume: 194
  start-page: 5110
  issue: 11
  year: 2015
  ident: 1555_CR26
  publication-title: J Immunol
  doi: 10.4049/jimmunol.1401810
– volume: 281
  start-page: 179
  issue: 1
  year: 2018
  ident: 1555_CR29
  publication-title: Immunol Rev
  doi: 10.1111/imr.12605
– volume: 11
  start-page: 1014
  issue: 11
  year: 2010
  ident: 1555_CR31
  publication-title: Nat Immunol
  doi: 10.1038/ni.1944
– volume: 30
  start-page: 2422
  issue: 11
  year: 2003
  ident: 1555_CR50
  publication-title: J Rheumatol
– volume: 7
  start-page: 416
  issue: 7
  year: 2011
  ident: 1555_CR54
  publication-title: Nat Rev Rheumatol
  doi: 10.1038/nrrheum.2011.68
– volume: 30
  start-page: 186
  issue: 2
  year: 1987
  ident: 1555_CR46
  publication-title: Arthritis Rheum
  doi: 10.1002/art.1780300209
– volume: 15
  start-page: gmr.15027616
  issue: 2
  year: 2016
  ident: 1555_CR55
  publication-title: Genet Mol Res
– volume: 3
  start-page: 394
  issue: 7
  year: 2002
  ident: 1555_CR9
  publication-title: Genes Immun
  doi: 10.1038/sj.gene.6363922
– volume: 66
  start-page: 642
  issue: 4
  year: 2014
  ident: 1555_CR20
  publication-title: Arthritis Care Res
  doi: 10.1002/acr.22194
– volume: 70
  start-page: 118
  issue: 2
  year: 1991
  ident: 1555_CR38
  publication-title: Medicine (Baltimore)
  doi: 10.1097/00005792-199103000-00004
– volume: 72
  start-page: 113
  issue: 1
  year: 2015
  ident: 1555_CR59
  publication-title: Cytokine
  doi: 10.1016/j.cyto.2014.11.025
– volume: 12
  start-page: 69
  year: 2014
  ident: 1555_CR24
  publication-title: J Transl Med
  doi: 10.1186/1479-5876-12-69
– volume: 30
  start-page: 222
  issue: 2
  year: 2016
  ident: 1555_CR1
  publication-title: Best Pract Res Clin Rheumatol
  doi: 10.1016/j.berh.2016.08.003
– volume: 111
  start-page: 15178
  issue: 42
  year: 2014
  ident: 1555_CR57
  publication-title: Proc Natl Acad Sci U S A
  doi: 10.1073/pnas.1416714111
– volume: 2012
  start-page: 879020
  year: 2012
  ident: 1555_CR45
  publication-title: Int J Inflamm
  doi: 10.1155/2012/879020
– volume: 44
  start-page: 1716
  issue: 7
  year: 2001
  ident: 1555_CR11
  publication-title: Arthritis Rheum
  doi: 10.1002/1529-0131(200107)44:7<1716::AID-ART298>3.0.CO;2-I
– volume: 63
  start-page: 1300
  issue: 10
  year: 2004
  ident: 1555_CR49
  publication-title: Ann Rheum Dis
  doi: 10.1136/ard.2003.013680
– volume: 16
  start-page: 1016
  issue: 10
  year: 2017
  ident: 1555_CR21
  publication-title: Autoimmun Rev
  doi: 10.1016/j.autrev.2017.07.017
– volume: 44
  start-page: 1172
  issue: 10
  year: 2017
  ident: 1555_CR60
  publication-title: J Dermatol
  doi: 10.1111/1346-8138.13888
– volume: 47
  start-page: 764
  issue: 9
  year: 1988
  ident: 1555_CR6
  publication-title: Ann Rheum Dis
  doi: 10.1136/ard.47.9.764
– volume: 114
  start-page: 2313
  issue: 9
  year: 2017
  ident: 1555_CR34
  publication-title: Proc Natl Acad Sci U S A
  doi: 10.1073/pnas.1619011114
– volume: 94
  start-page: e1554
  issue: 39
  year: 2015
  ident: 1555_CR17
  publication-title: Medicine (Baltimore)
  doi: 10.1097/MD.0000000000001554
– volume: 113
  start-page: 1411
  issue: 5
  year: 2016
  ident: 1555_CR33
  publication-title: Proc Natl Acad Sci U S A
  doi: 10.1073/pnas.1523212113
– volume: 56
  start-page: 3793
  issue: 11
  year: 2007
  ident: 1555_CR52
  publication-title: Arthritis Rheum
  doi: 10.1002/art.22981
– volume: 9
  start-page: e107183
  issue: 9
  year: 2014
  ident: 1555_CR36
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0107183
– volume: 61
  start-page: 345
  issue: 2
  year: 2013
  ident: 1555_CR48
  publication-title: Cytokine
  doi: 10.1016/j.cyto.2012.11.025
– volume: 341
  start-page: 1280
  issue: 8855
  year: 1993
  ident: 1555_CR7
  publication-title: Lancet
  doi: 10.1016/0140-6736(93)91184-N
– volume: 37
  start-page: 2369
  issue: 11
  year: 2010
  ident: 1555_CR39
  publication-title: J Rheumatol
  doi: 10.3899/jrheum.100247
– volume: 18
  start-page: 407
  issue: 4
  year: 2008
  ident: 1555_CR53
  publication-title: Mod Rheumatol
  doi: 10.3109/s10165-008-0065-9
– ident: 1555_CR2
  doi: 10.3109/07853890.2014.971052
– volume: 13
  start-page: 708
  issue: 7
  year: 2014
  ident: 1555_CR3
  publication-title: Autoimmun Rev
  doi: 10.1016/j.autrev.2014.01.058
– volume: 44
  start-page: 550
  issue: 3
  year: 2001
  ident: 1555_CR10
  publication-title: Arthritis Rheum
  doi: 10.1002/1529-0131(200103)44:3<550::AID-ANR103>3.0.CO;2-5
– volume: 9
  start-page: 739
  issue: 6
  year: 2015
  ident: 1555_CR56
  publication-title: Expert Rev Respir Med
  doi: 10.1586/17476348.2015.1109452
– volume: 9
  start-page: e95346
  issue: 5
  year: 2014
  ident: 1555_CR30
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0095346
SSID ssj0022924
Score 2.4049258
Snippet Interleukin (IL)-37 has been known to play an immunosuppressive role in various inflammatory disorders, but whether it participates in the regulation of...
Abstract Background Interleukin (IL)-37 has been known to play an immunosuppressive role in various inflammatory disorders, but whether it participates in the...
SourceID doaj
pubmedcentral
proquest
gale
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 54
SubjectTerms Adult
Adult-onset Still’s disease
Biomarkers - blood
Cells, Cultured
Cytokines
Disease Progression
Female
Humans
IL-37
Interleukin-1 - blood
Interleukins
Leukocytes, Mononuclear - metabolism
Male
Middle Aged
Peripheral blood mononuclear cells
Physiological aspects
Still's Disease, Adult-Onset - blood
Still's Disease, Adult-Onset - diagnosis
Young Adult
Title Interleukin-37 is increased in adult-onset Still’s disease and associated with disease activity
URI https://www.ncbi.nlm.nih.gov/pubmed/29566725
https://www.proquest.com/docview/2018013815
https://pubmed.ncbi.nlm.nih.gov/PMC5863797
https://doaj.org/article/6bbff7592085443f8e23a93477d65be3
Volume 20
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1fi9QwEA96gvgi_rd6LhUEQSjX5n8f9-SOQ7hD1IV9C2maYHHpie2--zX8en4SZ9LsukXQF19C6aQwyUwyM8n0N4S8CqyhAQxBUTndFhxMSmHBihV16WiwXDRVrBJxeSUvVvzdWqwPSn1hTtgEDzxN3IlsmhCUqLGWJOcsaE-ZrRlXqpWi8RHnE2zeLphKoRaFsCLdYVZangywUytMUgOehBCFnFmhCNb_55Z8YJPm-ZIHBuj8HrmbPMd8OXF8n9zw_QNy-zLdjT8kNh7ubfz2S9fDgs67Ie969AkH38JTHpE2CkyeHvOPY7fZ_Pz-Y8jTBU1u-za3SVTQH49nf9PcVGLiEVmdn316e1GkAgqFE4yORWWVbbWX3llBG-kkNpZ5FXiQzkmvPUpH-1IITVunLIuli4KGwJiVnD0mR_1175-S3FbU6YpXljnPYXpr8HxqEGdFS181bchIuZtQ4xK6OBa52JgYZWhpJhkYkIFBGRiZkTf7T75O0Bp_63yKUtp3RFTs-AJ0xSRdMf_SlYy8RhkbXLvAnLPpFwQYIqJgmaXgknIMojJyPOsJa87NyC93WmKQhIlqvb_eDoYiIFoFbpDIyJNJa_Y8U4hFpaJAUTN9mg1qTum7zxHyW2jJVK2e_Y9ZeE7uIJeYSEfpMTkav239C_CsxmZBbqq1WpBbp2dX7z8s4pKCdkWXvwAcIiJd
linkProvider Directory of Open Access Journals
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Interleukin-37+is+increased+in+adult-onset+Still%E2%80%99s+disease+and+associated+with+disease+activity&rft.jtitle=Arthritis+research+%26+therapy&rft.au=Huihui+Chi&rft.au=Dongzhou+Liu&rft.au=Yue+Sun&rft.au=Qiongyi+Hu&rft.date=2018-03-22&rft.pub=BMC&rft.eissn=1478-6362&rft.volume=20&rft.issue=1&rft.spage=1&rft.epage=12&rft_id=info:doi/10.1186%2Fs13075-018-1555-6&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_6bbff7592085443f8e23a93477d65be3
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1478-6362&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1478-6362&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1478-6362&client=summon